Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

39.12 -1.75 (-4.28%)
Official Closing Price Updated: 7:00 PM EDT, May 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 510,458
Open 39.86
Bid (Size) 25.10 (1)
Ask (Size) 41.07 (1)
Prev. Close 40.87
Today's Range 38.76 - 40.56
52wk Range 33.33 - 87.24
Shares Outstanding 47,333,554
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Glaukos Corporation Announces First Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire

Performance

YTD
-17.50%
-17.50%
1 Month
-33.99%
-33.99%
3 Month
-29.17%
-29.17%
6 Month
-21.24%
-21.24%
1 Year
-47.63%
-47.63%

More News

Read More
Glaukos Announces the Release of its 2021 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
From Glaukos Corporation
Via Business Wire
Glaukos: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 22, 2022
Via Benzinga
Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View
Via Benzinga
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces Executive Leadership Changes
From Glaukos Corporation
Via Business Wire
Analyst Ratings For Glaukos
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Via Benzinga
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Via Benzinga
Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile
Via Benzinga
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
From Glaukos Corporation
Via Business Wire
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
From Glaukos Corporation
Via Business Wire
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
From Glaukos Corporation
Via Business Wire
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher; All Eyes On Jobs Report
Via Benzinga
5 Stocks To Watch For January 7, 2022
Via Benzinga
Glaukos Announces FDA 510(k) Clearance of iPRIME™
From Glaukos Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.